Helicobacter pylori thiolperoxidase as a protective antigen in single- and multi-component vaccines

Vaccine

Volumn 30, Issue 50, 2012, Pages 7214-7220

  Stent, Andrew ^a   Every, Alison L ^a   Ng, Garrett Z ^a   Chionh, Yok T ^a   Ong, Lynette S ^a   Edwards, Stirling J ^b   Sutton, Philip ^a,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CSL LIMITED   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Helicobacter pylori; Multi antigen; Thiolperoxidase; Vaccine

Indexed keywords

ANTIOXIDANT; CATALASE; CHOLERA TOXIN; ENZYME; GENOMIC DNA; RECOMBINANT CATALASE; RECOMBINANT SUPEROXIDE DISMUTASE; SUPEROXIDE DISMUTASE; THIOLPEROXIDASE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED C57BL; PEROXIDASE;

EID: 84869880827     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.022     Document Type: Article

References (47)

1. Labenz J., Borsch G. Evidence for the essential role of Helicobacter pylori in gastric ulcer disease. Gut 1994, 35(January (1)):19-22.
2. Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001, 345(September (11)):784-789.
3. Wotherspoon A.C., Doglioni C., Diss T.C., Pan L.X., Moschini A., Deboni M., et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993, 342(8871):575-577.
4. Rupnow M.F., Chang A.H., Shachter R.D., Owens D.K., Parsonnet J. Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States. J Infect Dis 2009, 200(October (8)):1311-1317.
5. Ferrero R.L., Thiberge J.M., Huerre M., Labigne A. Recombinant antigens prepared from the urease subunits of Helicobacter spp.: evidence of protection in a mouse model of gastric infection. Infect Immun 1994, 62(11):4981-4989.
6. Ermak T.H., Giannasca P.J., Nichols R., Myers G.A., Nedrud J., Weltzin R., et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med 1998, 188(December (12)):2277-2288.
7. Guy B., Hessler C., Fourage S., Haensler J., Vialon-Lafay E., Rokbi B., et al. Systemic immunization with urease protects mice against Helicobacter pylori infection. Vaccine 1998, 16(May (8)):850-856.
8. Lee C.K., Weltzin R., Thomas W.D., Kleanthous H., Ermak T.H., Soman G., et al. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis 1995, 172(July (1)):161-172.
9. Corthesy-Theulaz I., Porta N., Glauser M., Saraga E., Vaney A.C., Haas R., et al. Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology 1995, 109(July (1)):115-121.
10. Yang X.L., Liu W.C., Yang W.W., Zhong D., Liu Y.H., Zhang J.D., et al. Oral immunization of mice with vaccine of attenuated Salmonella typhimurium expressing Helicobacter pylori urease B subunit. Biomed Environ Sci 2005, 18(December (6)):411-418.
11. Ghiara P., Rossi M., Marchetti M., Di Tommaso A., Vindigni C., Ciampolini F., et al. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect Immun 1997, 65(December (12)):4996-5002.
12. Ferrero R.L., Thiberge J.M., Kansau I., Wuscher N., Huerre M., Labigne A. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci U S A 1995, 92(July (14)):6499-6503.
13. Sutton P., Doidge C., Pinczower G., Wilson J., Harbour S., Swierczak A., et al. Effectiveness of vaccination with recombinant HpaA from Helicobacter pylori is influenced by host genetic background. FEMS Immunol Med Microbiol 2007, 50(July (2)):213-219.
14. Satin B., Del Giudice G., Della Bianca V., Dusi S., Laudanna C., Tonello F., et al. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med 2000, 191(May (9)):1467-1476.
15. Comtois S.L., Gidley M.D., Kelly D.J. Role of the thioredoxin system and the thiol-peroxidases Tpx and Bcp in mediating resistance to oxidative and nitrosative stress in Helicobacter pylori. Microbiology 2003, 149(January (Pt 1)):121-129.
16. Olczak A.A., Seyler R.W., Olson J.W., Maier R.J. Association of Helicobacter pylori antioxidant activities with host colonization proficiency. Infect Immun 2003, 71(January (1)):580-583.
17. Backert S., Kwok T., Schmid M., Selbach M., Moese S., Peek R.M., et al. Subproteomes of soluble and structure-bound Helicobacter pylori proteins analyzed by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005, 5(April (5)):1331-1345.
18. Mullaney E., Brown P.A., Smith S.M., Botting C.H., Yamaoka Y.Y., Terres A.M., et al. Proteomic and functional characterization of the outer membrane vesicles from the gastric pathogen Helicobacter pylori. Proteomics Clin Appl 2009, 3(July (7)):785-796.
19. Park J.W., Song J.Y., Lee S.G., Jun J.S., Park J.U., Chung M.J., et al. Quantitative analysis of representative proteome components and clustering of Helicobacter pylori clinical strains. Helicobacter 2006, 11(December (6)):533-543.
20. Radcliff F., Hazell S., Koleznikow T., Doige C., Lee A. Catalase, a novel antigen for Helicobacter pylori vaccination. Infect Immun 1997, 65(11):4668-4674.
21. Every A.L., Stent A., Moloney M.B., Ng G.Z., Skene C.D., Edwards S.J., et al. Evaluation of superoxide dismutase from Helicobacter pylori as a protective vaccine antigen. Vaccine 2011, 29(February (7)):1514-1518.
22. Olczak A.A., Olson J.W., Maier R.J. Oxidative-stress resistance mutants of Helicobacter pylori. J Bacteriol 2002, 184(June (12)):3186-3193.
23. Lee A., O'Rourke J., De Ungria M.C., Robertson B., Daskalopoulos G., Dixon M.F. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 1997, 112(April (4)):1386-1397.
24. Alm R.A., Ling L.S.L., Moir D.T., King B.L., Brown E.D., Doig P.C., et al. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 1999, 397(6715):176-180.
25. Liu S., Tobias R., McClure S., Styba G., Shi Q., Jackowski G. Removal of endotoxin from recombinant protein preparations. Clin Biochem 1997, 30(August (6)):455-463.
26. Marklund S., Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974, 47(September (3)):469-474.
27. Rho B.S., Hung L.W., Holton J.M., Vigil D., Kim S.I., Park M.S., et al. Functional and structural characterization of a thiol peroxidase from Mycobacterium tuberculosis. J Mol Biol 2006, 361(September (5)):850-863.
28. Skene C.D., Doidge C., Sutton P. Evaluation of ISCOMATRIX and ISCOM vaccines for immunisation against Helicobacter pylori. Vaccine 2008, 26(July (31)):3880-3884.
29. Sutton P., Wilson J., Kosaka T., Wolowczuk I., Lee A. Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies. Immunol Cell Biol 2000, 78(February (1)):28-30.
30. Sutton P., Wilson J., Lee A. Further development of the Helicobacter pylori mouse vaccination model. Vaccine 2000, 18(24):2677-2685.
31. Roussel Y., Harris A., Lee M.H., Wilks M. Novel methods of quantitative real-time PCR data analysis in a murine Helicobacter pylori vaccine model. Vaccine 2007, 25(April (15)):2919-2929.
32. Cleveland D.W., Fischer S.G., Kirschner M.W., Laemmli U.K. Peptide mapping by limited proteolysis in sodium dodecyl sulfate and analysis by gel electrophoresis. J Biol Chem 1977, 252(February (3)):1102-1106.
33. Garhart C.A., Redline R.W., Nedrud J.G., Czinn S.J. Clearance of Helicobacter pylori infection and resolution of postimmunization gastritis in a kinetic study of prophylactically immunized mice. Infect Immun 2002, 70(July (7)):3529-3538.
34. Nielsen H., Andersen L.P. Activation of human phagocyte oxidative metabolism by Helicobacter pylori. Gastroenterology 1992, 103(December (6)):1747-1753.
35. Davies G.R., Simmonds N.J., Stevens T.R., Sheaff M.T., Banatvala N., Laurenson I.F., et al. Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo. Gut 1994, 35(February (2)):179-185.
36. Bagchi D., Bhattacharya G., Stohs S.J. Production of reactive oxygen species by gastric cells in association with Helicobacter pylori. Free Radic Res 1996, 24(June (6)):439-450.
37. Seyler R.W., Olson J.W., Maier R.J. Superoxide dismutase-deficient mutants of Helicobacter pylori are hypersensitive to oxidative stress and defective in host colonization. Infection and Immunity 2001, 69(6):4034-4040.
38. Harris A.G., Wilson J.E., Danon S.J., Dixon M.F., Donegan K. Catalase (KatA) and KatA-associated protein (KapA) are essential to persistent colonization in the Helicobacter pylori SS1 mouse model. Microbiology 2003, 149:665-672.
39. O'Riordan A.A., Morales V.A., Mulligan L., Faheem N., Windle H.J., Kelleher D.P. Alkyl hydroperoxide reductase: a candidate Helicobacter pylori vaccine. Vaccine 2012, 30(June (26)):3876-3884.
40. Orsborn K.I., Shubitz L.F., Peng T., Kellner E.M., Orbach M.J., Haynes P.A., et al. Protein expression profiling of Coccidioides posadasii by two-dimensional differential in-gel electrophoresis and evaluation of a newly recognized peroxisomal matrix protein as a recombinant vaccine candidate. Infect Immun 2006, 74(March (3)):1865-1872.
41. Nandakumar R., Nandakumar M.P., Marten M.R., Ross J.M. Proteome analysis of membrane and cell wall associated proteins from Staphylococcus aureus. J Proteome Res 2005, 4(March-April (2)):250-257.
42. Rosenkrands I., King A., Weldingh K., Moniatte M., Moertz E., Andersen P. Towards the proteome of Mycobacterium tuberculosis. Electrophoresis 2000, 21(November (17)):3740-3756.
43. Rossi G., Ruggiero P., Peppoloni S., Pancotto L., Fortuna D., Lauretti L., et al. Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy. Infect Immun 2004, 72(June (6)):3252-3259.
44. Malfertheiner P., Schultze V., Rosenkranz B., Kaufmann S.H.E., Ulrichs T., Novicki D., et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 2008, 135(3):787-795.
45. Wu C., Shi Y., Guo H., Zou W.Y., Guo G., Xie Q.H., et al. Protection against Helicobacter pylori infection in mongolian gerbil by intragastric or intramuscular administration of H. pylori multicomponent vaccine. Helicobacter 2008, 13(June (3)):191-199.
46. Insel R.A. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. Ann N Y Acad Sci 1995, 754(May):35-47.
47. Blanchard T.G., Czinn S.J., Redline R.W., Sigmund N., Harriman G., Nedrud J.G. Antibody-independent protective mucosal immunity to gastric Helicobacter infection in mice. Cell Immunol 1999, 191(January (1)):74-80.